Allogeneic stem cell transplantation for relapsed primary central nervous system lymphoma: Is it feasible?

[1]  M. Pfreundschuh,et al.  High-dose chemotherapy with autologous haematopoietic stem cell support for relapsed or refractory primary CNS lymphoma: a prospective multicentre trial by the German Cooperative PCNSL study group , 2017, Leukemia.

[2]  E. Weissinger,et al.  Immune Reconstitution after Allogeneic Hematopoietic Stem Cell Transplantation , 2016, Front. Immunol..

[3]  R. Houot,et al.  Primary CNS lymphoma at first relapse/progression: characteristics, management, and outcome of 256 patients from the French LOC network. , 2016, Neuro-oncology.

[4]  J. Finlay,et al.  Graft versus tumor effect in the brain of a child with recurrent metastatic medulloblastoma , 2015, Pediatric blood & cancer.

[5]  Min Yang,et al.  High-dose methotrexate plus temozolomide as a salvage treatment in metastatic central nervous system Lymphoma: two cases report and review of literature. , 2015, International journal of clinical and experimental medicine.

[6]  E. Phillips,et al.  Primary CNS Lymphoma , 2014, Current Hematologic Malignancy Reports.

[7]  A. Brandes,et al.  MATILDE chemotherapy regimen for primary CNS lymphoma , 2014, Neurology.

[8]  L. Deangelis,et al.  Methotrexate re-challenge for recurrent primary central nervous system lymphoma , 2014, Journal of Neuro-Oncology.

[9]  M. Reni,et al.  Current uses of radiation therapy in patients with primary CNS lymphoma , 2013, Expert review of anticancer therapy.

[10]  S. Opat,et al.  Rituximab is associated with improved survival for aggressive B cell CNS lymphoma. , 2013, Neuro-oncology.

[11]  M. Dreyling,et al.  Prognosis of patients with primary central nervous system lymphoma after high-dose chemotherapy followed by autologous stem cell transplantation , 2013, Haematologica.

[12]  J. Finke,et al.  Prognosis after high-dose chemotherapy followed by autologous stem-cell transplantation as first-line treatment in primary CNS lymphoma--a long-term follow-up study. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  E. Thiel,et al.  High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. , 2010, The Lancet. Oncology.

[14]  F. Cavalli,et al.  High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial , 2009, The Lancet.

[15]  K. Hoang-Xuan,et al.  Primary CNS lymphoma in immunocompetent patients. , 2009, The oncologist.

[16]  K. Hoang-Xuan,et al.  Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  F. Feuerhake,et al.  High-dose chemotherapy and autologous stem-cell transplantation without consolidating radiotherapy as first-line treatment for primary lymphoma of the central nervous system , 2008, Haematologica.

[18]  D. Crawford,et al.  Treatment of Epstein-Barr-virus-associated primary CNS B cell lymphoma with allogeneic T-cell immunotherapy and stem-cell transplantation. , 2005, The Lancet. Oncology.

[19]  J. Blay,et al.  Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  K. Hoang-Xuan,et al.  Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  T. Ruhstaller,et al.  Rituximab: active treatment of central nervous system involvement by non-Hodgkin's lymphoma? , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  A. Nagler,et al.  Graft-versus-lymphoma effect after allogeneic peripheral blood stem cell transplantation for primary central nervous system lymphoma. , 1999, Leukemia & lymphoma.

[23]  L. Lockman,et al.  Microglia: The Effector Cell for Reconstitution of the Central Nervous System following Bone Marrow Transplantation for Lysosomal and Peroxisomal Storage Diseases , 1995 .

[24]  D. Nelson,et al.  Non-Hodgkin's lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315. , 1992, International journal of radiation oncology, biology, physics.